FDA delays Kadmon’s priority review as apparent clampdown continues

FDA delays Kadmon’s priority review as apparent clampdown continues

Source: 
Endpoints
snippet: 

Kadmon Holdings just lost their priority review.

The immunology biotech announced Wednesday that the FDA has pushed back the decision date for their graft-versus-host disease drug belumosudil by three months, after the agency requested additional information from the drugmaker. That will effectively turn their 6-month priority review into a 9-month one, just below the FDA’s standard decision-making deadline.